A research and development Blueprint for action to prevent epidemics

Public consultation on preferred profile for epidemic vaccine manufacturing platforms

Manufacturing platforms are needed to support development of vaccines in the event of an epidemic. The R&D Blueprint aims to provide preferred characteristics for such platforms to support funders and industry groups in making well informed decisions. WHO is seeking comments on the document below, which was developed by the CEPI secretariat and is shared with their consent. Comments may be submitted by individuals or organizations through the form attached below and sent to chuaa@who.int – with name and affiliation. Deadline is COB 20 May 2017. Note that all comments may be made publicly available at a later stage. WHO will publish the finalized preferred profile for epidemic vaccine manufacturing platforms after taking into account comments received.

Public consultation on target product profile for Lassa Fever vaccine

Lassa Fever is a disease in the WHO R&D Blueprint list of epidemic threats needing urgent R&D action. WHO has just published a draft Lassa Fever vaccine target product profile for preventive use, which is now available for public consultation. Comments may be submitted by individuals or organizations through the form attached below and sent to chuaa@who.int – with name and affiliation. Deadline is COB 2 May 2017 Note that all comments may be made publicly available at a later stage. WHO will publish the finalized Lassa Fever target product profile after taking into account comments received.

WHO publishes a detailed report on prioritization of diseases that need urgent R&D

WHO publishes a detailed report on the revised list of priority diseases that need urgent R&D in order to prevent public health emergencies in the near future. The list includes nine disease categories for which few or no medical countermeasures exist due to market failures or lack of scientific knowledge. The diseases provide the basis for work on the WHO R&D Blueprint for emergency preparedness and response. The current list of diseases builds on the first such list developed by a coalition of international experts convened by WHO in November 2015.

Public consultation on target product profile for a Nipah virus vaccine

Nipah virus (NiV) is one of the pathogens in the WHO R&D Blueprint list of epidemic threats needing urgent R&D attention. From 1998 to 2015, more than 600 cases of Nipah virus (NiV) human infections were reported. Later outbreaks, in India and Bangladesh, have caused death in 43% to 100% of infected patients. WHO has just published a draft NiV vaccine target product profile, which is now available for public consultation. Comments may be submitted by individuals or organizations through the form attached below and sent to chuaa@who.int - with your name and affiliation. Deadline is COB 13 April 2017. Note that all comments may be made publicly available at a later stage. WHO will publish the finalized NiV vaccine target product profile after integrating the comments received.

WHO publishes revised Zika vaccine profile

Zika Virus remains an enduring public health challenge likely to cause future outbreaks that put susceptible populations at risk, thus requiring intense R&D action. A first Zika vaccine target product profile (TPP), describing the preferred product characteristics for vaccines, was published in July 2016. Due to rapidly evolving evidence, a robust review was done in November 2016 incorporating the latest emerging data. The revised Zika Vaccine TPP is now available.

Update on the R&D Blueprint Activities

Read the latest on Blueprint achievements and activities to improve R&D preparedness during public health emergencies. A list of anticipated benefits for the three areas of work is available here below.

Towards Better Zika Diagnostic Tests

There is a need to continue the global scientific effort to gain a better understanding of the Zika virus, its vectors, modes of transmission and the natural history of the disease. Key to this effort is having an accurate diagnosis of Zika virus infection, however, available tests are limited by several factors. WHO’s current R&D activities on Zika diagnostics are summarized in this publication in PLoS NTD. WHO will continue its R&D work on Zika under the WHO R&D Blueprint effort.



About R&D Blueprint

The R&D Blueprint is a global strategy and preparedness plan to ensure that targeted R&D can strengthen the emergency response by bringing medical technologies to patients during epidemics.

Prioritized Diseases

Full list of Blueprint priority pathogens »

Diseases for which R&D preparedness activities are already in development

Ebola » MERS-CoV » Zika » Nipah » Lassa Fever »

3 approaches for key actions

Meetings & events